In a test-negative design case-control study, Dr. Thiago Cerqueira-Silva and colleagues, investigate the effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland.
In a test-negative design case-control study, Dr. Thiago Cerqueira-Silva and colleagues, investigate the effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland.
Older people, those with multimorbidity, and those with specific underlying health
conditions remain at increased risk of COVID-19 hospitalisation and death after the
initial vaccine booster and should, therefore, be prioritised for additional boosters,
including novel optimised versions, and the increasing array of COVID-19 therapeutics.
By Aug 10, 2022, 3 497 208 of the estimated 4·4 million adults living in Scotland
had received three doses of a COVID-19 vaccine. However, a proportion of the adult
population remains unvaccinated (defined as no record of any vaccine being administered)
and susceptible to severe COVID-19 outcomes. Characterising this population can help
to understand gaps in vaccine coverage and determinants of vaccine hesitancy and could
support targeted public health messaging. Unlike the vaccinated population, on whom
information is gathered at the point of vaccination, current estimates of the unvaccinated
population are calculated using general practitioner (GP) records.
A slight decrease in numbers was also detected for uptake of vaccines in England for the same period, March to July 2020.Experts say more research is needed to understand what factors potentially affected the increase in Scotland to help guide future